AR117715A1 - Interferón hiperglicosilado con inmunogenicidad reducida - Google Patents
Interferón hiperglicosilado con inmunogenicidad reducidaInfo
- Publication number
- AR117715A1 AR117715A1 ARP190103715A ARP190103715A AR117715A1 AR 117715 A1 AR117715 A1 AR 117715A1 AR P190103715 A ARP190103715 A AR P190103715A AR P190103715 A ARP190103715 A AR P190103715A AR 117715 A1 AR117715 A1 AR 117715A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon
- reduced immunogenicity
- hyperglycosylated
- nucleic acid
- acid molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
| BR112022011975A BR112022011975A2 (pt) | 2019-12-17 | 2020-12-16 | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo |
| PCT/US2020/065246 WO2021126929A1 (en) | 2019-12-17 | 2020-12-16 | Modified interferon-alpha-2 having reduced immunogenicity |
| US17/783,948 US20230127506A1 (en) | 2019-12-17 | 2020-12-16 | Modified interferon-alpha-2 having reduced immunogenicity |
| MX2022007546A MX2022007546A (es) | 2019-12-17 | 2020-12-16 | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. |
| EP20901063.6A EP4076504A4 (en) | 2019-12-17 | 2020-12-16 | MODIFIED INTERFERON ALPHA-2 WITH REDUCED IMMUNOGENICITY |
| JP2022537837A JP7786010B2 (ja) | 2019-12-17 | 2020-12-16 | 免疫原性が低下した修飾インターフェロン-アルファ-2 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117715A1 true AR117715A1 (es) | 2021-08-25 |
Family
ID=76478524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230127506A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4076504A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7786010B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR117715A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022011975A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007546A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021126929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| KR20250048583A (ko) | 2022-08-18 | 2025-04-09 | 리제너론 파아마슈티컬스, 인크. | 인터페론 전구단백질 및 이의 용도 |
| KR20260026098A (ko) | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| CN116814595B (zh) * | 2023-08-30 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种腺苷脱氨酶突变体及其固定化 |
| WO2026104336A1 (en) | 2024-11-13 | 2026-05-21 | F. Hoffmann-La Roche Ag | Immunoconjugates |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| EP1379555A2 (en) * | 2001-03-02 | 2004-01-14 | MERCK PATENT GmbH | Modified interferon alpha with reduced immunogenicity |
| MX2007001589A (es) * | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas. |
| KR20080026135A (ko) | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | 개선된 인간 인터페론 분자 및 이의 용도 |
| JP5208733B2 (ja) | 2005-06-29 | 2013-06-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 組換えインターフェロンα2(IFNα2)変異体 |
| AR057215A1 (es) | 2006-12-01 | 2007-11-21 | Univ Nac Del Litoral Unl | Proteina de fusion |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| CA2695543A1 (en) | 2007-08-06 | 2009-02-12 | Schering Corporation | Gamma secretase modulators |
| PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| AR102120A1 (es) * | 2015-09-29 | 2017-02-08 | Univ Nac Del Litoral | Interferón modificado con inmunogenicidad reducida |
| JP7534215B2 (ja) | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
-
2019
- 2019-12-17 AR ARP190103715A patent/AR117715A1/es unknown
-
2020
- 2020-12-16 WO PCT/US2020/065246 patent/WO2021126929A1/en not_active Ceased
- 2020-12-16 EP EP20901063.6A patent/EP4076504A4/en active Pending
- 2020-12-16 BR BR112022011975A patent/BR112022011975A2/pt not_active IP Right Cessation
- 2020-12-16 JP JP2022537837A patent/JP7786010B2/ja active Active
- 2020-12-16 US US17/783,948 patent/US20230127506A1/en active Pending
- 2020-12-16 MX MX2022007546A patent/MX2022007546A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022007546A (es) | 2022-11-30 |
| BR112022011975A2 (pt) | 2022-08-30 |
| WO2021126929A1 (en) | 2021-06-24 |
| EP4076504A4 (en) | 2024-04-10 |
| JP2023514659A (ja) | 2023-04-07 |
| JP7786010B2 (ja) | 2025-12-16 |
| EP4076504A1 (en) | 2022-10-26 |
| US20230127506A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010559A (es) | Polipéptidos efectores de crispr-cas y métodos de uso de estos. | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| BR112018073909A2 (pt) | proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas | |
| MX2022014411A (es) | Polipéptidos il-12 activables y métodos de uso de estos. | |
| ATE479704T1 (de) | Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv | |
| AR087091A1 (es) | Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso | |
| IL262805B2 (en) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
| DK1668031T3 (da) | Homogene præparater af IL-29 | |
| AR087227A1 (es) | CONJUGADO DE INTERFERON a CON POLIETILENGLICOL | |
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| IL288541B (en) | Vaccine against rsv | |
| CL2019003409A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| MY206268A (en) | Modified s1 subunit of the coronavirus spike protein | |
| JP2017513503A5 (cg-RX-API-DMAC7.html) | ||
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
| BR112021023957A2 (pt) | Peptídeos | |
| BR112022010321A2 (pt) | Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase | |
| PE20251395A1 (es) | Proteinas de fusion de hmpv de prefusion estabilizadas | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| CA2692358A1 (en) | Recombinant human interferon-like proteins | |
| CO2023000048A2 (es) | Conjugados de citoquina | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 |